Novo has returned for Milestone's latest round, having led its $55m series C last year, helping the cardiovascular drug developer's total funding to $167m.

Canada-based cardiovascular therapy developer Milestone Pharmaceuticals has closed an $80m financing round that included pharmaceutical firm Novo, increasing its overall funding to more than $167m. The round was led by RTW Investments and included Venrock Healthcare Capital Partners, Boxer Capital, Forbion, Domain Associates, BDC Capital, Pappas Capital, Go Capital, Fonds de solidarité FTQ and funds…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.